Rifampicin-resistant and rifabutin-susceptible mycobacterium tuberculosis strains: A breakpoint artefact?

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2074-2077

  Schon T ^a,b   Jureen P ^c   Chryssanthou, E ^d   Giske, C G ^d   Kahlmeter, G ^e,f   Hoffner, S ^c   Angeby K ^d  

^a KALMAR COUNTY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Swedish Institute for Communicable Disease Control   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e Växjö Hospital   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

Ecoffs; Epidemiological cut offs; Hiv; Mdr; Mics; Minimal inhibitory concentrations; Multidrug resistant tuberculosis; Rpob

Indexed keywords

RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ARTICLE; ARTIFACT; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG DETERMINATION; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; WILD TYPE;

ECOFFS; EPIDEMIOLOGICAL CUT-OFFS; HIV; MDR; MICS; MINIMAL INHIBITORY CONCENTRATIONS; MULTIDRUG-RESISTANT TUBERCULOSIS; RPOB;

BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; RIFABUTIN; RIFAMPIN;

EID: 84882598507     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt150     Document Type: Article

References (20)

1. Kahlmeter G, Brown DF, Goldstein FW et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 2006; 12: 501-3.
2. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995; 8: 496-514.
3. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007; issue 4: CD005159.
4. Rifabutin. Tuberculosis (Edinb) 2008; 88: 145-7.
5. Ji B, Truffot-Pernot C, Lacroix C et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1541-6.
6. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000; 49: 185-9.
7. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
8. Rusch-Gerdes S, Pfyffer GE, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
9. Schon T, Jureen P, Chryssanthou E et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011; 15: 502-9.
10. Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141: 626-30.
11. Schon T, Jureen P, Giske CG et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009; 64: 786-93.
12. Jureen P, Werngren J, Hoffner SE. Evaluation of the line probe assay (LiPA) for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2004; 84: 311-6.
13. Hauck Y, Fabre M, Vergnaud G et al. Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. J Antimicrob Chemother 2009; 64: 259-62.
14. Cavusoglu C, Karaca-Derici Y, Bilgic A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10: 662-5.
15. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council. Tuber Lung Dis 1992; 73: 59-67.
16. Gillespie SH, Baskerville AJ, Davidson RN et al. The serum rifabutin concentrations in a patient successfully treated for multi-resistant Mycobacterium tuberculosis infection. J Antimicrob Chemother 1990; 25: 490-1.
17. Pretet S, Lebeaut A, Parrot R et al. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection). Eur Respir J 1992; 5: 680-4.
18. Jo KW, Ji W, Hong Y et al. The efficacy of rifabutin for rifabutinsusceptible, multidrug-resistant tuberculosis. Respir Med 2013; 107: 292-7.
19. Williamson DA, Roberts SA, Bower JE et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012; 16: 216-20.
20. Chan SL, Yew WW, Ma WK et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis 1992; 73: 33-8.